Aptorum Group Limited (NASDAQ:APM) Short Interest Down 47.6% in September

Aptorum Group Limited (NASDAQ:APM) saw a large drop in short interest in September. As of September 30th, there was short interest totalling 2,200 shares, a drop of 47.6% from the September 15th total of 4,200 shares. Based on an average daily volume of 15,400 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the company’s stock are sold short.

Aptorum Group Stock Performance

APM opened at $1.73 on Friday. The company’s fifty day moving average price is $2.65 and its two-hundred day moving average price is $4.40. Aptorum Group has a 1-year low of $1.35 and a 1-year high of $17.49. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.18 and a current ratio of 1.18.

Institutional Investors Weigh In On Aptorum Group

A hedge fund recently bought a new stake in Aptorum Group stock. Murchinson Ltd. purchased a new stake in Aptorum Group Limited (NASDAQ:APM) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 14,000 shares of the company’s stock, valued at approximately $133,000. Murchinson Ltd. owned about 0.27% of Aptorum Group at the end of the most recent quarter. 3.80% of the stock is currently owned by institutional investors and hedge funds.

Aptorum Group Company Profile

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.